JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Pfizer

Geschlossen

BrancheGesundheitswesen

24.59 0.04

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

24.55

Max

24.91

Schlüsselkennzahlen

By Trading Economics

Einkommen

2.6B

3B

Verkäufe

-4B

14B

KGV

Branchendurchschnitt

17.051

34.393

EPS

0.92

Dividendenrendite

7.19

Gewinnspanne

21.677

Angestellte

81,000

EBITDA

2.5B

5.1B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+16.31% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

7.19%

2.54%

Nächstes Ergebnis

28. Okt. 2025

Nächste Dividendenausschüttung

2. Sept. 2025

Nächstes Ex-Dividendendatum

7. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-12B

134B

Vorheriger Eröffnungskurs

24.55

Vorheriger Schlusskurs

24.59

Nachrichtenstimmung

By Acuity

39%

61%

125 / 374 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pfizer Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Aug. 2025, 11:34 UTC

Ergebnisse

Pfizer Boosts 2025 Adjusted EPS Outlook Following 2Q Gains

5. Aug. 2025, 20:44 UTC

Ergebnisse

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 18:20 UTC

Ergebnisse

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5. Aug. 2025, 18:17 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5. Aug. 2025, 16:04 UTC

Market Talk

Pfizer's New Tax Rate Helps Boost Adj EPS Outlook -- Market Talk

5. Aug. 2025, 15:25 UTC

Ergebnisse

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5. Aug. 2025, 13:56 UTC

Ergebnisse

Pfizer Stock Rises as Earnings Smash Expectations. But These Challenges Remain. -- Barrons.com

5. Aug. 2025, 11:43 UTC

Ergebnisse

Pfizer Stock Pops as Earnings Smash Expectations. Guidance Hiked in Face of Tariffs. -- Barrons.com

5. Aug. 2025, 11:27 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:57 UTC

Ergebnisse

Pfizer Stock Pops as Earnings Smash Expectations. Why the Outlook Has Been Hiked. -- Barrons.com

5. Aug. 2025, 10:55 UTC

Ergebnisse

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5. Aug. 2025, 10:53 UTC

Ergebnisse

Pfizer Boosts 2025 Profit Estimate In A Sign Of 'Confidence' -- MarketWatch

5. Aug. 2025, 10:51 UTC

Ergebnisse

Pfizer: On Track to Deliver About $7.2B Overall Cost Savings From Cost-Improvement Initiatives b/ End of 2027 >PFE

5. Aug. 2025, 10:50 UTC

Ergebnisse

Pfizer: Expects to Continue to De-Lever in Prudent Manner to Maintain Balanced Capital-Allocation Strategy >PFE

5. Aug. 2025, 10:49 UTC

Ergebnisse

Pfizer: Current Financial Guidance Doesn't Anticipate Any Share Repurchases in 2025 >PFE

5. Aug. 2025, 10:49 UTC

Ergebnisse

Pfizer Now Sees 2025 Effective Tax Rate on Adjusted Income About 13%; Had Seen About 15% >PFE

5. Aug. 2025, 10:48 UTC

Ergebnisse

Pfizer Cuts Adjusted R&D Expenses View to $10.4-$11.4B From $10.7B-$11.7B >PFE

5. Aug. 2025, 10:48 UTC

Ergebnisse

Pfizer: Guidance Absorbs Impact of Potential Price Changes This Year Based on Letter Received July 31 From President Trump >PFE

5. Aug. 2025, 10:47 UTC

Ergebnisse

Pfizer: Guidance Absorbs Impact of Currently Imposed Tariffs From China, Canada, Mexico >PFE

5. Aug. 2025, 10:46 UTC

Ergebnisse

Pfizer Had Seen 2025 Adjusted EPS $2.80-$3.00 >PFE

5. Aug. 2025, 10:45 UTC

Ergebnisse

Pfizer Raises 2025 EPS Guidance >PFE

5. Aug. 2025, 10:45 UTC

Ergebnisse

Pfizer 2Q EPS 51c >PFE

5. Aug. 2025, 10:45 UTC

Ergebnisse

Pfizer Sees FY Adj EPS $2.90-Adj EPS $3.10 >PFE

5. Aug. 2025, 10:45 UTC

Ergebnisse

Pfizer 2Q Adj EPS 78c >PFE

5. Aug. 2025, 10:45 UTC

Ergebnisse

Pfizer 2Q Rev $14.7B >PFE

5. Aug. 2025, 10:45 UTC

Ergebnisse

Pfizer Sees FY Rev $61B-$64B >PFE

4. Aug. 2025, 15:26 UTC

Ergebnisse

Pfizer Reports Earnings Soon. The Stock Is Slumping for a Reason. -- Barrons.com

30. Juli 2025, 18:36 UTC

Ergebnisse

UPS Stock Joins 7% Yielders in S&P 500. Here's Who Else Is in the Club. -- Barrons.com

9. Juli 2025, 09:17 UTC

Heiße Aktien

Stocks to Watch Wednesday: Freeport-McMoRan, Glencore, Novo Nordisk -- WSJ

10. Juni 2025, 12:18 UTC

Ergebnisse

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

Peer-Vergleich

Kursveränderung

Pfizer Prognose

Kursziel

By TipRanks

16.31% Vorteil

12-Monats-Prognose

Durchschnitt 28.59 USD  16.31%

Hoch 33 USD

Tief 24 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pfizer – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

6

Buy

12

Halten

0

Sell

Technischer Score

By Trading Central

22.855 / 23.85Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

125 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.